Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al

QR Code

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al

Antonio Ieni,1 Valeria Barresi,1 Giuseppina Rosaria Rita Ricciardi,2 Barbara Adamo,3 Vincenzo Adamo,2 Giovanni Tuccari11Department of Human Pathology of Adult and Evolutive Age “Gaetano Barresi”, Section of Pathology, University of Messina, AOU “Policlinico G Martino&am...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ieni A, Barresi V, Ricciardi GRR, Adamo B, Adamo V, Tuccari G
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2016
Sujets:	triple-negative breast cancer molecular subtype targeted therapy androgen receptor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/24c93d61b5f947e195d2a24577096ac4
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Triple-negative breast cancer: treatment challenges and solutions
par: Collignon J, et autres
Publié: (2016)

IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI
par: Amna Ameer, et autres
Publié: (2021)

IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI
par: Amna Ameer, et autres
Publié: (2021)

Antiangiogenic therapy for breast cancer with triple negative phenotype
par: Inna P. Ganshina, et autres
Publié: (2021)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
par: Marina K. Ibragimova, et autres
Publié: (2021)

Opportunities for metastatic triple negative breast cancer therapy
par: Inna P. Ganshina, et autres
Publié: (2021)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
par: Fleisher B, et autres
Publié: (2016)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
par: Alberto Aranza-Martínez, et autres
Publié: (2021)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
par: da Silva JL, et autres
Publié: (2021)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
par: Inna P. Ganshina, et autres
Publié: (2021)

<i>SMARCA4</i> Depletion Induces Cisplatin Resistance by Activating YAP1-Mediated Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer
par: Jihyun Kim, et autres
Publié: (2021)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
par: Xupeng Bai, et autres
Publié: (2021)

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers
par: Al-saraireh YM, et autres
Publié: (2021)

Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells
par: Cook MT, et autres
Publié: (2016)

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
par: Corey Speers, et autres
Publié: (2017)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
par: Zilin Zhang, et autres
Publié: (2021)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
par: Luis de la Cruz-Merino, et autres
Publié: (2021)

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
par: Mirjana Prvanović, et autres
Publié: (2021)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
par: Ye J, et autres
Publié: (2016)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
par: Peng Su, et autres
Publié: (2021)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
par: Sara Bravaccini, et autres
Publié: (2021)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
par: Miyuki Kitahara, et autres
Publié: (2021)

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
par: Ilie SM, et autres
Publié: (2018)

Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer
par: Jin X, et autres
Publié: (2020)

Palmatine sensitizes chemoresistant triple negative breast cancer cells via efflux inhibition of multidrug resistant protein 1.
par: Selase Ativui, et autres
Publié: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
par: Giacomo Barchiesi, et autres
Publié: (2021)

Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients
par: Wen S, et autres
Publié: (2020)

Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
par: Zuo R, et autres
Publié: (2021)

Therapeutic Effects of Dietary Soybean Genistein on Triple-Negative Breast Cancer via Regulation of Epigenetic Mechanisms
par: Manvi Sharma, et autres
Publié: (2021)

Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer
par: Wenjie Zhao, et autres
Publié: (2021)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
par: Hana Kim, et autres
Publié: (2021)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
par: Jesse Lopes da Silva, et autres
Publié: (2021)

ARNTL2 is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer
par: Wang X, et autres
Publié: (2021)

Prognostic and clinicopathological values of tissue expression of MFAP5 and ITM2A in triple-negative breast cancer: an immunohistochemical study
par: Abdulwahab Abuderman, et autres
Publié: (2020)

A triple negative breast cancer: what it is not!
par: Katakkar SB
Publié: (2012)

Triple negative breast cancer: an Indian perspective
par: Akhtar M, et autres
Publié: (2015)

Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification
par: Yubao Zhang, et autres
Publié: (2021)

Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells
par: Veronica Vella, et autres
Publié: (2021)

A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
par: Bingqing Xia, et autres
Publié: (2021)

THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY
par: A. I. Chertkova, et autres
Publié: (2018)